PositiveID President Lyle L. Probst Discusses How the Company’s Firefly Dx Could be Used to Detect Ebola in Minutes at the Point of Need

DELRAY BEACH, Fla., Oct. 16, 2014 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that its President, Lyle L. Probst, was featured on Fox Business’ The Willis Report yesterday to discuss how the Company’s point-of-need pathogen detection system, Firefly Dx, could be used anywhere to detect Ebola within minutes. The interview can be viewed at: http://www.foxbusiness.com/on-air/willis-report/videos#p/157870/v/3841659343001.

Joining Mr. Probst for the interview was PositiveID advisory board member Thomas DiNanno, who previously served as Deputy Assistant Secretary for Critical Infrastructure Protection at the U.S. Department of Homeland Security.

PositiveID’s Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time PCR (polymerase chain reaction) chemistry. Firefly is being developed to meet the growing need in healthcare markets for more rapid and accurate point-of-need diagnostics that will enable hospitals, physicians, military personnel, and others to save lives. Firefly is designed to derive results from a sample in less than 20 minutes, at the point of need, compared to two to four hours for a lab device, which could enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of biological detection systems for America’s homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

Statements about PositiveID’s future expectations, including, without limitation, the likelihood that its Firefly Dx system could be used to detect Ebola in minutes at the point of need; the likelihood that Firefly is being developed to meet the growing need in healthcare markets for more rapid and accurate point-of-need diagnostics that will enable hospitals, physicians, military personnel, and others to save lives; the likelihood that Firefly could enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems; and all statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the bio-threat detection and rapid medical testing sectors; the Company’s ability to raise capital; the Company’s ability to complete the development of its Firefly system; as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 11, 2014, and 10-Qs filed on August 14, 2014, May 20, 2014, and November 19, 2013, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

PositiveID Corporation
Allison Tomek
561-805-8000